MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss applicable
to common...
-$15,530,937
Revenues
$587,882
European Union
$207,054
Non European Union
$18,781
Revenues
$1,654
Net loss
-$14,032,342
Deemed dividend series
c preferred stock
$1,498,595
Change in fair value of
series d warrant...
$10,377,638
Other Revenues
$587,882
Product Sales
$225,835
Development Service
$1,654
Change in fair value of
series e warrant...
-$4,486,847
Change in fair value of
subscription agreement...
$3,127,962
Gain on forgiveness
of accounts...
$944,694
Other income
$226,041
Change in fair value of
contingent warrant...
-$16,499
Interest income
$2
Loss before income
taxes
-$14,031,817
Income tax (expense)
benefit
$525
Total other income
(expense)
$3,825,039
Revenue
$815,371
Loss on
extinguishment of note payable
-$5,384,719
Change in fair value of
series d derivative...
$3,809,333
Loss on issuance of
preferred stock and...
$3,674,329
Change in fair value of
series e derivative...
$1,539,014
Interest expense
$751,005
Loss on
extinguishment of preferred...
$196,244
Loss from operations
-$17,856,856
Gross profit
$632,913
Cost of revenue
$182,458
Total operating
expenses
$18,489,769
Research and development
-$66,133
Impairment of goodwill
$11,512,000
Selling, general and
administrative
$7,043,902
Back
Back
Income Statement
source: myfinsight.com
Onconetix, Inc. (ONCO)
Onconetix, Inc. (ONCO)